What Is GLOW Peptide? GHK-Cu, BPC-157 and TB-500 in One Vial
GLOW is a fixed research blend of three separately studied peptides: GHK-Cu (50 mg), BPC-157 (10 mg) and TB-500 (10 mg), 70 mg in total in the standard vial. Each component has its own literature, mostly cell-culture and rodent work. No published study examines the three together, so nothing in the component literature can be attributed to the blend itself.
A blend is a supply format, not a finding. The studies cited here examined GHK-Cu, BPC-157 or thymosin beta-4 one at a time, mostly in cell and animal models. Nothing here is medical guidance and none of it describes the blend. Research context only.
At a glance
| Component | What it is | What the literature covers | Standard vial |
|---|---|---|---|
| GHK-Cu | A three-residue peptide (glycyl-L-histidyl-L-lysine) that binds copper(II) and occurs naturally in human plasma | Cell-culture, gene-expression and skin-model work, reviewed in 2015 and 2018 | 50 mg |
| BPC-157 | A 15-residue peptide (GEPPPGKPADDAGLV) from a gastric protein sequence | A 2025 systematic review found 36 studies: 35 preclinical and 1 retrospective clinical study | 10 mg |
| TB-500 | A synthetic peptide built around the actin-binding region of thymosin beta-4, a 43-residue protein | Thymosin beta-4 biology: actin binding, cell migration, wound-repair models | 10 mg |
| GLOW | Fixed 50 : 10 : 10 ratio | No study of the three together | 70 mg |
The catalogue also lists 30 mg and 90 mg GLOW vials. They change only the GHK-Cu amount (10 mg and 70 mg); BPC-157 and TB-500 stay at 10 mg each.
What each component’s evidence actually looks like
GHK-Cu. GHK is found in human plasma, saliva and urine and is reported to decline with age. Reviews of its biology describe effects on collagen, decorin and metalloproteinase activity in fibroblast and skin models, plus broad gene-expression changes in cell data (Pickart et al., 2015; Pickart & Margolina, 2018). The 2015 review lists a company R&D department as the authors’ affiliation, which is worth knowing when weighing how strongly it is worded.
BPC-157. A 2025 systematic review in HSS Journal covered the literature to June 2024: 544 articles, 36 studies included, 35 of them preclinical and one clinical. The clinical study was a retrospective report in 12 patients, and the authors found no clinical safety data. They also report a half-life of less than 30 minutes (Vasireddi et al., 2025).
TB-500. Thymosin beta-4 is the main actin-sequestering protein in cells. Its central actin-binding stretch (residues 17–23, LKKTETQ) is the region the research-market fragment is modelled on, and short sequences containing it have been reported to promote cell migration and wound healing in cell and animal models (Sosne et al., 2010; Goldstein et al., 2005).
A 2026 narrative review in Sports Medicine covered GHK-Cu, BPC-157, thymosin beta-4 and TB-500 among the unapproved peptides marketed directly to patients. It found that many show favourable tissue-repair outcomes in animal models, but that rigorous human safety data are scarce and that serious harm is possible (Mendias & Awan, 2026).
Why a blend exists, and what it cannot show
A fixed blend exists for handling: one vial to prepare instead of three. That is a convenience, and it has a cost in what a result can mean.
- It cannot attribute an observation. Anything seen with the blend cannot be assigned to GHK-Cu, to BPC-157, to TB-500, or to an interaction between them.
- It does not merge the components’ properties. They are three different molecules of different sizes with different reported clearance. Putting them in one vial does not give them a shared profile.
- The ratio is a constraint of the format. We found no study testing whether a 50 : 10 : 10 ratio is meaningful for any endpoint.
- It has no literature of its own. We could not find a published pharmacokinetic, stability, interaction or efficacy study of the three administered together, and New-U’s own product record says the same.
GLOW and KLOW
KLOW is the same three compounds at the same amounts plus KPV at 10 mg, which brings the total to 80 mg. The two blends therefore share the evidence limits above. The KLOW vs GLOW page sets the two side by side, and What is KLOW peptide? covers the four-component version.
What to look for in documentation
A blend raises the bar for paperwork, because a single figure can hide a missing component.
- Each component named and reported. A certificate should identify all three peptides, not just report one total.
- Amount, not only purity. An HPLC purity percentage is the share of one chromatographic trace; it does not show that each component is present at its labelled amount. The limits of a peptide COA are set out separately.
- Method and date stated. Identity by mass spectrometry and purity by HPLC, with the method and the date on the document. How to read a certificate of analysis walks through the checks.
Research takeaway
- GLOW is GHK-Cu, BPC-157 and TB-500 at a fixed 50 : 10 : 10 ratio, 70 mg in the standard vial.
- The component evidence is cell-culture and animal work; BPC-157’s clinical record is one retrospective 12-patient report.
- There is no study of the blend, so component findings cannot be credited to it.
- The blend has no marketing authorisation as a medicine and is sold for laboratory research only.
Primary sources
- BioMed Research International — GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration (Pickart et al., 2015)
- International Journal of Molecular Sciences — Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (Pickart & Margolina, 2018)
- HSS Journal — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi et al., 2025)
- Trends in Molecular Medicine — Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues (Goldstein et al., 2005)
- FASEB Journal — Biological activities of thymosin beta4 defined by active sites in short peptide sequences (Sosne et al., 2010)
- Sports Medicine — Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Mendias & Awan, 2026)
GLOW as laboratory research material
New-U lists GLOW (GHK-Cu, BPC-157 and TB-500) as laboratory research material. Its Certificate of Analysis is published on the GLOW COA page. The studies above describe the individual components, not this blend. Research use only – all claims made on this site are for testing and research use only.
View GLOWFrequently asked questions
What is in GLOW peptide?
The standard GLOW vial contains GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg, 70 mg in total. The 30 mg and 90 mg vials change only the GHK-Cu amount (10 mg and 70 mg). The ratio is fixed within each size.
Is there research on GLOW itself?
No. We could not find a published study of GHK-Cu, BPC-157 and TB-500 administered together, and New-U’s own product record says none exists. The components have separate literatures, mostly cell-culture and animal work.
Why is GLOW supplied as a blend?
For handling: one vial to prepare instead of three. It is a supply format rather than a pharmacological rationale, and it means a result cannot be attributed to an individual component.
How does GLOW differ from KLOW?
KLOW is the same three compounds at the same amounts plus KPV at 10 mg, giving 80 mg in total.
Is GLOW approved for human use?
No. GLOW has no marketing authorisation as a medicine and is supplied for laboratory research only, not for human consumption.
External links are provided for research reference only; New-U is not affiliated with the cited organisations or authors. All figures are published study results shown for research context, not dosing guidance. New-U Research Compounds supplies research compounds strictly for laboratory research use only — not for human consumption.
Part of the Tissue repair & recovery research research area — explore related compounds, guides and sources.